UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 18, 2014

 

ONCOSEC MEDICAL INCORPORATED

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-54318

 

98-0573252

(State or other jurisdiction

 

(Commission

 

(I.R.S. Employer

of incorporation)

 

File Number)

 

Identification No.)

 

9810 Summers Ridge Road, Suite 110
San Diego, California

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (855) 662-6732

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07                                           Submission of Matters to a Vote of Security Holders.

 

On July 18, 2014, OncoSec Medical Incorporated (the “Company”) held its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) at the Company’s principal executive offices located as 9810 Summers Ridge Road, Suite 110, San Diego, California 92121.

 

The final voting results on the matters presented at the Annual Meeting were as follows:

 

Proposal 1 — To elect four directors to the Company’s Board of Directors to serve for a term of one year or until successors are duly elected and qualified.

 

Directors

 

For

 

Withheld

 

Broker Non-Votes

 

Dr. Avtar Dhillon

 

41,112,818

 

2,172,898

 

127,035,339

 

Dr. Anthony Maida

 

41,366,019

 

1,919,697

 

127,035,339

 

Dr. James DeMesa

 

41,286,019

 

1,999,697

 

127,035,339

 

Punit Dhillon

 

40,754,531

 

2,531,185

 

127,035,339

 

 

Proposal 2 — To ratify the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2014.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

161,742,142

 

7,428,061

 

1,150,852

 

 

 

Proposal 3 — To approve the amendment and restatement of the Company’s 2011 Stock Incentive Plan (the “2011 Plan”) to, among other things, increase the share reserve available under the 2011 Plan by 16,000,000 shares, add an “evergreen” share renewal provision to commence on the first business day of the 2015 calendar year, and increase the annual per person limit on stock options, stock appreciation rights, restricted stock and restricted stock units that are intended to qualify for exclusion from the federal tax deduction limitation under Section 162(m) of the Internal Revenue Code.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

34,121,439

 

8,550,033

 

614,244

 

127,035,339

 

 

1



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ONCOSEC MEDICAL INCORPORATED

 

 

Dated: July 23, 2014

By:

/s/ Punit Dhillon

 

 

Name: Punit Dhillon

 

 

Title: President & Chief Executive Officer

 

2